Top

Annals of Surgical Oncology

Published in:

01-06-2007 | Breast Oncology

Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer

Authors: Simon R. Davies, MRCS, Gareth Watkins, BSc, Robert E. Mansel, MS, FRCS, Wen G. Jiang, MD

Published in: Annals of Surgical Oncology | Issue 6/2007

Abstract

Background

The CCN family has three Wnt-inducted secreted proteins named WISP-1, WISP-2 and WISP-3. These molecules are known to play a diverse role in cells, but their role in cancer cells remains controversial.

Methods

In this study, we analyzed the expression of the three WISP molecules at the mRNA and protein levels in a cohort of 122 human breast tumors and 32 normal breast tissues, and we correlated these findings with patients’ clinical outcomes.

Results

WISP-1 transcripts were found in lower levels in node-positive tumors compared with node-negative tumors (P < .05); were lower in patients with a moderate (P = .01) and poor Nottingham Prognostic Index prognosis (P < .05) compared with good prognostic groups; were of significantly lower level in grade 3 differentiated tumors (P < .05) compared with grade 1; and were of lower levels in patients who developed metastasis and died from breast cancer–related causes (P < .05 in both comparisons). Almost the reverse was found to be true for WISP-2, which had greater levels of expression in node-positive tumors (P = .0043); higher levels in both moderate and poor prognostic groups compared with the good prognostic group (both P < .05); greater level in both grade 2 and 3 when compared with grade 1 (both P < .05); and higher levels in patients who went on to develop metastases (P < .01). WISP-3 transcript levels showed no statistically significant differences between groups.

Conclusions

WISPs may play important but contrasting roles in breast cancer. WISP-1 seems to act as a tumor suppressor and WISP-2 as a factor that stimulates aggressiveness; WISP-3 has no definable beneficial or detrimental role.

Planque N, Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int 2003; 3:15–30PubMedCrossRef

Bringstock D. The CCN family: a new stimulus package. J Endocrinol 2003; 178:169–75CrossRef

Perbal B, Brigstock D, Lau L. Report on the second international workshop on the CCN family of genes. Mol Pathol 2003; 56:80–5PubMedCrossRef

Leask A, Abraham DJ. All in the CCN family: essential matricellular signalling modulators emerge from the bunker. J Cell Sci 2006; 119:4803–10PubMedCrossRef

Xie D, Nakachi K, Wang H, Elashoff R, Koeffler P. Elevated levels of connective tissue growth factor, WISP-1 and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61:8917–23PubMed

Pennica D, Swanson T, Welsh J, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1 transformed cells and aberrantly expressed in human colon tumours. Proc Natl Acad Sci U S A 1998; 95:14717–22PubMedCrossRef

Khor T, Gul Y, Ithnin H, Seow H. A comparative study of the expression of Wnt-1, WISP-1, surviving and cyclin-D1 in colorectal cancer. Int J Colorectal Dis 2006; 21:291–300PubMedCrossRef

Soon L, Yie T, Shvarts Levine A, Su F, Tchou-Wong K. Overexpression of WISP-1 down regulated motility and invasion of lung cancer cells through inhibition of rac activation. J Biol Chem 2003; 278:11465–70PubMedCrossRef

Banerjee S, Sengupta K, Saxena N, Dhar K, Banerjee S. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-α–positive breast tumour calls through multipul modular cross-talks. Mol Cancer Res 2005; 3:151–62PubMedCrossRef

10.

Banerjee S, Saxena N, Sengupta K, Tawfik O, Mayo M, Banerjee S. WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation. Neoplasia 2003; 5:63–73PubMed

11.

Nessling M, Richter K, Schwaenen C, et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res 2005; 65:439–47PubMed

12.

Chappell S, Walsh T, Walker RA, Shaw J. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br J Cancer 1997; 76:1558–61PubMed

13.

Kleer C, Zhang Q, Lan Q, Merajver S. WISP3 (CCN6) is a gercreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer. Neoplasia 2004; 6:179–85PubMedCrossRef

14.

Zhang Y, Pan Q, Zhong H, Merajver S, Kleer C. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res 2005; 7:1080–9CrossRef

15.

Hanavadi S, Martin T, Mansel R, Jiang W. Interleukin-11 and its receptor expression in human breast cancer. Ann Surg Oncol 2006; 13:802–8PubMedCrossRef

16.

Martin T, Goyal A, Mansel R, Watkins G, Jiang W. The transcription factor for the E-cadherin complex, Twist, Slug and Snail, in human breast cancer. Ann Surg Oncol 2005; 12:1–9CrossRef

17.

Jiang W, Watkins G, Lane J, et al. Prognostic value of Rho family and rho-GDIs in breast cancer. Clin Can Res 2003; 9:6432–40

18.

Nazarenko A, Bhatnagar S, Hohman R. A closed tube format for amplification and detection of DNA based on energy transfer. Nucleic Acids Res 1997; 25:2516–21PubMedCrossRef

19.

Jiang W, Douglas-Jones A, Mansel R. Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. Int J Cancer 2003; 106:752–7PubMedCrossRef

20.

Ye L, Martin T, Parr C, Harrison G, Mansel R, Jiang W. Biphasic effects of 17-β-oestradiol on expression of occluding and transendothelial resistance (TER) and paracellular permiabiliy in human vascular endothelial cells. J Cell Physiol 2003; 196:362–9PubMedCrossRef

21.

King J, Ofori-Acquash A, Stevens T, Al-Mehdi A, Fodstad O, Jiang W. Activated leukocyte adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 2004; 6:478–87CrossRef

22.

Parr C, Watkins G, Jiang W. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 2004; 14:779–86PubMed

23.

Jiang W, Grimshaw D, Lane J, et al. A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin Cancer Res 2001; 7:2555–62. Erratum in: Clin Cancer Res 2002; 8:300PubMed

24.

Davies G, Jiang W, Mason M. Cell-cell adhesion and signalling intermediates in human prostate cancer. J Urol 2000; 163:985–92PubMedCrossRef

25.

Jiang WG, Watkins G, Fodstad O, et al. Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11:781–91PubMedCrossRef

26.

Martin TA, Watkins G, Lane J, Jiang WG. Assessing mircovessels and angiogenesis in human cancer, using VE-cadherin. Histopathology 2005; 46:422–30PubMedCrossRef

27.

Davies G, Rmaili K, Jiang WG. Tumour endothelial marker-8 (TEM-8) in human breast cancer: the correlation with angiogenesis. Int J Oncol 2006; 29:1311–7PubMed

28.

Davies G, Mason MD, Mansel RE, Jiang WG. Expression of tumour-endothelial markers in human breast cancer. Clin Exp Metastasis 2004; 21:31–7PubMedCrossRef

29.

Jiang W, Watkins G, Fodsrad O, Douglas-Jones A, Mokbel K, Mansel R. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Endocr Relat Cancer 2004; 11:781–91PubMedCrossRef

30.

Babic A, Kireeva M, Kolesnikova T, Lau L. CYR61, a product of a growth factor–inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998; 2695:6355–60CrossRef

31.

Mason H, Lake A, Wubben J, Nowak R, Castellot J Jr. The growth arrest–specific gene CCN5 is deficient in human leiomyomas and inhibits the proliferation and motility of cultured human uterine smooth muscle cells. Mol Hum Reprod 2004; 10:181–7PubMedCrossRef

32.

Zoubine M, Banerjee S, Saxena N, Campbell D, Banerjee S. WISP-2: a serum-induible gene differentially expressed in human normal breast epithelial cells and in MCF-7 breast tumor cells. Biochem Biophys Res Commun 2001; 282:421–5PubMedCrossRef

33.

Van Golen K, Davies S, Wu Z, et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5:2511–9PubMed

34.

Thorstensen L, Diep C, Meling G, et al. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 2001; 121:1275–80PubMedCrossRef

Title: Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer
Authors: Simon R. Davies, MRCS
Gareth Watkins, BSc
Robert E. Mansel, MS, FRCS
Wen G. Jiang, MD
Publication date: 01-06-2007
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-007-9376-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Differential Expression and Prognostic Implications of the CCN Family Members WISP-1, WISP-2, and WISP-3 in Human Breast Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2007

Lymphedema Therapy Reduces the Volume of Edema and Pain in Patients with Breast Cancer

Treatment and Outcome of 82 Patients with Angiosarcoma

Society of Surgical Oncology Heritage Award: Honoring Edward M. Copeland III, MD, FACS

Teaching Palliative Care and End-of-Life Issues: A Core Curriculum for Surgical Residents

Regional Lymph Node Metastases; a Singular Manifestation of the Process of Clinical Metastases in Cancer: Contemporary Animal Research and Clinical Reports Suggest Unifying Concepts

α1,2Fucosylation Is a Superior Predictor of Postoperative Prognosis for Colorectal Cancer Compared with Blood Group A, B, or Sialyl Lewis X Antigen Generated within Colorectal Tumor Tissues